Barclays
SPPI

Barclays’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Barclays’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,500
Closed -$15K – 5708
2020
Q2 		$15K Sell
4,500
-500
-10% -$1.46K ﹤0.01% 5265
2020
Q1 		$12K Sell
5,000
-7,200
-59% -$19.7K ﹤0.01% 5782
2019
Q4 		$44K Buy
12,200
+2,600
+27% +$21K ﹤0.01% 5773
2019
Q3 		$80K Sell
9,600
-216,300
-96% -$1.75M ﹤0.01% 5641
2019
Q2 		$1.95M Buy
225,900
+222,900
+7,430% +$1.99M ﹤0.01% 2953
2019
Q1 		$32K Buy
3,000
+1,400
+88% +$15K ﹤0.01% 6149
2018
Q4 		$14K Sell
1,600
-24,900
-94% -$317K ﹤0.01% 6062
2018
Q3 		$445K Buy
26,500
+24,800
+1,459% +$537K ﹤0.01% 4372
2018
Q2 		$36K Sell
1,700
-3,800
-69% -$70.4K ﹤0.01% 5857
2018
Q1 		$88K Buy
5,500
+100
+2% +$1.98K ﹤0.01% 5474
2017
Q4 		$102K Buy
+5,400
New +$97.8K ﹤0.01% 5229
2017
Q3 		– Sell
-1,100
Closed -$8K – 7113
2017
Q2 		$8K Buy
+1,100
New +$7.19K ﹤0.01% 6126
2016
Q4 		– Sell
-2,000
Closed -$9K – 6907
2016
Q3 		$9K Buy
2,000
+500
+33% +$2.96K ﹤0.01% 5843
2016
Q2 		$10K Sell
1,500
-1,000
-40% -$7.07K ﹤0.01% 5553
2016
Q1 		$15K Buy
2,500
+1,400
+127% +$7.18K ﹤0.01% 5344
2015
Q4 		$7K Buy
1,100
+700
+175% +$4K ﹤0.01% 5502
2015
Q3 		$2K Sell
400
-7,000
-95% -$48.6K ﹤0.01% 6397
2015
Q2 		$44K Sell
7,400
-1,700
-19% -$10.8K ﹤0.01% 5241
2015
Q1 		$55K Sell
9,100
-23,200
-72% -$154K ﹤0.01% 5215
2014
Q4 		$194K Buy
32,300
+4,200
+15% +$30.9K ﹤0.01% 4663
2014
Q3 		$225K Buy
28,100
+6,300
+29% +$49.3K ﹤0.01% 4640
2014
Q2 		$174K Sell
21,800
-20,900
-49% -$159K ﹤0.01% 4944
2014
Q1 		$299K Buy
42,700
+9,200
+27% +$77.9K ﹤0.01% 4404
2013
Q4 		$268K Sell
33,500
-9,300
-22% -$83.1K ﹤0.01% 4711
2013
Q3 		$342K Sell
42,800
-21,200
-33% -$172K ﹤0.01% 4511
2013
Q2 		$477K Buy
+64,000
New +$491K ﹤0.01% 4257

Other funds holding SPPI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Barclays's SPPI Position: Q2 2022 in Review

Barclays sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2022, closing a stake of 26,470 shares — an estimated $34K sold.

Barclays first reported a position in SPPI in Q2 2013 and held it in 36 quarters. The position peaked at $20.6M in Q4 2017. 86 funds tracked by Wall St. Rank hold SPPI as of Q2 2022.

  • Barclays reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 26,470 Spectrum Pharmaceuticals Inc shares in Q2 2022, an estimated $34K.
  • Barclays first reported a position in Spectrum Pharmaceuticals Inc in Q2 2013 and held it in 36 quarters.
  • Barclays's Spectrum Pharmaceuticals Inc position peaked at $20.6M in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.